Fulcrum Asset Management LLP raised its position in Boston Scientific Corporation (NYSE:BSX – Free Report) by 164.8% during the third quarter, Holdings Channel reports. The firm owned 126,489 shares of the medical equipment provider’s stock after purchasing an additional 78,726 shares during the period. Fulcrum Asset Management LLP’s holdings in Boston Scientific were worth $5,550,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Avantax Planning Partners Inc. increased its position in shares of Boston Scientific by 4.0% during the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock worth $329,000 after buying an additional 201 shares during the period. Natural Investments LLC lifted its holdings in Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after buying an additional 206 shares during the period. 180 Wealth Advisors LLC lifted its holdings in Boston Scientific by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after buying an additional 223 shares during the period. MGO One Seven LLC boosted its position in Boston Scientific by 1.9% during the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock valued at $614,000 after acquiring an additional 260 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its position in Boston Scientific by 1.4% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,918 shares of the medical equipment provider’s stock valued at $870,000 after acquiring an additional 268 shares during the last quarter. 89.07% of the stock is owned by institutional investors.
Boston Scientific Trading Up 2.9%
BSX opened at $44.00 on Tuesday. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $105.65. The company has a current ratio of 1.36, a quick ratio of 0.74 and a debt-to-equity ratio of 0.42. The company has a market cap of $63.78 billion, a P/E ratio of 18.64, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. The company has a fifty day moving average price of $44.26 and a two-hundred day moving average price of $55.46.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. Analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. TD Cowen downgraded Boston Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the company from $56.00 to $46.00 in a research note on Friday, October 30th. Needham & Company LLC decreased their target price on Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, October 28th. Piper Sandler lowered their target price on Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, July 29th. Oppenheimer lowered Boston Scientific from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 29th. Finally, Argus lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.
View Our Latest Research Report on Boston Scientific
Boston Scientific Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.
Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Boston Scientific serves healthcare providers and patients around the world.
Further Reading
- Five stocks we like better than Boston Scientific
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
